COVID-19 Cross-sectional Study in Maricá, Brazil: The Impact of Vaccination Coverage on Viral Incidence

Population surveillance in COVID-19 Pandemic is crucial to follow up the pace of disease and its related immunological status. Here we present a cross-sectional study done in Maricá, a seaside town close to the city of Rio de Janeiro, Brazil. Three rounds of study sampling, enrolling a total of 1134 subjects, were performed during May to August 2021. Here we show that the number of individuals carrying detectable IgG antibodies and the neutralizing antibody (NAb) levels were greater in vaccinated groups compared to unvaccinated ones, highlighting the importance of vaccination to attain noticeable levels of populational immunity against SARS-CoV-2. Moreover, we found a decreased incidence of COVID-19 throughout the study, clearly correlated with the level of vaccinated individuals as well as the proportion of individuals with detectable levels of IgG anti-SARS-CoV-2 and NAb. The observed drop occurred even during the introduction of the Delta variant in Maricá, what suggests that the vaccination slowed down the widespread transmission of this variant. Overall, our data clearly support the use of vaccines to drop the incidence associated to SARS-CoV-2.

Citing Articles

Seroprevalence of SARS-CoV-2 and Vaccination Coverage among Residents of a Lower-Middle-Class Population in the Federal District, Brazil.

Nogueira de Brito R, Teixeira A, Gontijo C, Da Silva Faria R, Ramalho W, Romero G Vaccines (Basel). 2023; 11(5).

PMID: 37243020 PMC: 10220777. DOI: 10.3390/vaccines11050916.

References

Li F, Li Y, Liu M, Fang L, Dean N, Wong G . Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. Lancet Infect Dis. 2021; 21(5):617-628. PMC: 7833912. DOI: 10.1016/S1473-3099(20)30981-6. View

Allen H, Vusirikala A, Flannagan J, Twohig K, Zaidi A, Chudasama D . Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study. Lancet Reg Health Eur. 2021; 12:100252. PMC: 8552812. DOI: 10.1016/j.lanepe.2021.100252. View

Ioannou P, Karakonstantis S, Astrinaki E, Saplamidou S, Vitsaxaki E, Hamilos G . Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers. Infect Dis (Lond). 2021; 53(11):876-879. PMC: 8240538. DOI: 10.1080/23744235.2021.1945139. View

Miraglia J, Monteiro C, Giannecchini Romagnolo A, Xavier Gomes R, Pitangueiras Mangueira C, Rosseto-Welter E . A seroprevalence survey of anti-SARS-CoV-2 antibodies among individuals 18 years of age or older living in a vulnerable region of the city of São Paulo, Brazil. PLoS One. 2021; 16(7):e0255412. PMC: 8320930. DOI: 10.1371/journal.pone.0255412. View

Lalwani P, Araujo-Castillo R, Ganoza C, Salgado B, Pereira Filho I, da Silva D . High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort. Lancet Glob Health. 2021; 9(11):e1508-e1516. PMC: 8525986. DOI: 10.1016/S2214-109X(21)00355-7. View

Tabak Y, Sun X, Brennan T, Chaguturu S . Incidence and Estimated Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Among Persons Tested in US Retail Locations, May 1 to August 7, 2021. JAMA Netw Open. 2021; 4(12):e2143346. PMC: 8696565. DOI: 10.1001/jamanetworkopen.2021.43346. View

Luo C, Morris C, Sachithanandham J, Amadi A, Gaston D, Li M . Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals. medRxiv. 2021; . PMC: 8404894. DOI: 10.1101/2021.08.15.21262077. View

Horta B, Silveira M, Barros A, Barros F, Hartwig F, Dias M . Prevalence of antibodies against SARS-CoV-2 according to socioeconomic and ethnic status in a nationwide Brazilian survey. Rev Panam Salud Publica. 2020; 44:e135. PMC: 7595003. DOI: 10.26633/RPSP.2020.135. View

Ng O, Marimuthu K, Koh V, Pang J, Linn K, Sun J . SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. Lancet Infect Dis. 2020; 21(3):333-343. PMC: 7831879. DOI: 10.1016/S1473-3099(20)30833-1. View

10.

Deckert A, Anders S, De Allegri M, Nguyen H, Souares A, McMahon S . Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial. Trials. 2021; 22(1):39. PMC: 7791150. DOI: 10.1186/s13063-020-04982-z. View

11.

Knoll M, Wonodi C . Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2020; 397(10269):72-74. PMC: 7832220. DOI: 10.1016/S0140-6736(20)32623-4. View

12.

Bichara C, Queiroz M, da Silva Graca Amoras E, Vaz G, Vallinoto I, Bichara C . Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil. Vaccines (Basel). 2021; 9(10). PMC: 8539673. DOI: 10.3390/vaccines9101169. View

13.

Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan M, Perez-Olmeda M . Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020; 396(10250):535-544. PMC: 7336131. DOI: 10.1016/S0140-6736(20)31483-5. View

14.

Suthar M, Arunachalam P, Hu M, Reis N, Trisal M, Raeber O . Durability of immune responses to the BNT162b2 mRNA vaccine. Med. 2022; 3(1):25-27. PMC: 9304003. DOI: 10.1016/j.medj.2021.12.005. View

15.

Vicenti I, Basso M, Gatti F, Scaggiante R, Boccuto A, Zago D . Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. Int J Infect Dis. 2021; 112:40-44. PMC: 8410637. DOI: 10.1016/j.ijid.2021.08.052. View

16.

Favresse J, Gillot C, Di Chiaro L, Eucher C, Elsen M, Van Eeckhoudt S . Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. Viruses. 2021; 13(7). PMC: 8309994. DOI: 10.3390/v13071364. View

17.

Alves J, Engel L, de Vasconcelos Cabral R, Rodrigues E, Ribeiro L, Higa L . A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. Sci Rep. 2021; 11(1):18428. PMC: 8445915. DOI: 10.1038/s41598-021-97330-3. View

18.

Freire-Paspuel B, Vega-Marino P, Velez A, Cruz M, Garcia-Bereguiain M . "Sample pooling of RNA extracts to speed up SARS-CoV-2 diagnosis using CDC FDA EUA RT-qPCR kit". Virus Res. 2020; 290:198173. PMC: 7513759. DOI: 10.1016/j.virusres.2020.198173. View

19.

Girgis S, Hafez H, Elarab H, Sherif B, Sabry M, Afifi I . SARS-CoV-2 PCR positivity rate and seroprevalence of related antibodies among a sample of patients in Cairo: Pre-wave 2 results of a screening program in a university hospital. PLoS One. 2021; 16(7):e0254581. PMC: 8282003. DOI: 10.1371/journal.pone.0254581. View

20.

Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V . Analysis of the Delta Variant B.1.617.2 COVID-19. Clin Pract. 2021; 11(4):778-784. PMC: 8544471. DOI: 10.3390/clinpract11040093. View